Providers

Real-world data show no significant differences in overall survival between patients with or without cytogenetic risk factors.

The findings support the clinical benefits of delandistrogene moxeparvovec in patients with Duchenne muscular dystrophy (DMD).

Outcomes were evaluated among children born between April 1980 and June 2019 by using data from 12 observational birth cohorts from the Environmental Influences on Child Health Outcomes Children’s Respiratory and Environmental Workgroup.

RGX-202 shows promising efficacy in Duchenne muscular dystrophy, improving functional outcomes and biomarker expression in early trial results.

The timing of immunotherapy initiation is not a significant factor in the outcomes of patients with extensive-stage small cell lung cancer (ES-SCLC), a study found.

Patients who remained on treatment, especially at higher doses or on tirzepatide, were more likely to achieve clinically meaningful weight loss and improved glycemic control.

Subcutaneous mosunetuzumab shows promising efficacy and safety in high-tumor burden follicular lymphoma, paving the way for outpatient treatment options.

With a 42% reduction seen in the use of hematopoietic stem cell transplantation (HSCT) throughout the decade, researchers suggest that transplantation may be reserved for more fit patients.

About 40% of people living with HIV in an international survey did not make joint decisions regarding treatment with their provider despite reporting a high amount of trust.

A new report suggests a noninvasive means to evaluate portal hypertension in patients with BCR::ABL1-negative myeloproliferative neoplasms.

A meta-analysis suggests allogeneic stem cell transplantation (allo-SCT) should not be recommended following first-line autologous stem cell transplant (auto-SCT).

The findings are notable in part because therapies have already been approved to target C5aR1 in other diseases.

While citing overwhelming barriers patients in rural areas face when accessing care, providers noted the potential of telehealth to improve access in a survey.

TP53 aberrations and circulating tumor DNA burden were found to be predictors of poor outcomes in high-risk patients with large B-cell lymphoma.

The findings provide insight into which patients may have favorable or inferior responses to immunotherapy for small cell lung cancer (SCLC).

Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.

Zanubrutinib showed long-term efficacy in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and deletion of the 17p chromosome, with progression-free survival similar to patients without high-risk disease characteristics.

Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion independence compared with erythropoiesis-stimulating agents (ESAs) in a real-world analysis.

The 2025 European Hematology Association (EHA) Congress, convening virtually and in Milan, Italy, from June 12 to June 15, 2025, will feature a revamped program structure for the meeting’s 30th anniversary while maintaining ample opportunities to network, debate, and absorb practice-changing findings in hematology and oncology.

This observational evaluation compared an adult medical care coordination intervention with usual care and found that the intervention was associated with significant improvements in patient activation.

The CDC urges all travelers to be fully vaccinated against measles amid rising cases in the US, some linked with international travel.

Older adults with cardiovascular disease (CVD) or CVD risk factors report that gaps in communication among their providers are common and hazardous.

Trastuzumab deruxtecan plus pertuzumab shows promising results as a potential new first-line treatment for HER2-positive breast cancer at ASCO 2025.

Researchers found a causal association between insomnia and atopic dermatitis and identified several genetic variations contributing to the association.

Fecal immunochemical testing (FIT) was more accurate than blood-based testing for detecting advanced precancerous colorectal lesions, a comparative study found.